Biodexa Pharmaceuticals (BDRX) Total Liabilities (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Total Liabilities of $9.0 million for Q4 2025, up 99.36% sequentially from $4.5 million in Q2 2025, and up 8.71% YoY from $8.3 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Total Liabilities (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Total Liabilities for 13 years, with the latest figure at $9.0 million in Q4 2025.
- Quarterly Total Liabilities rose 8.71% year-over-year to $9.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.0 million (up 8.71% YoY) and the FY2025 annual result came in at $8.9 million, up 7.75% from the prior year.
- Total Liabilities improved to $9.0 million in Q4 2025 per BDRX's latest filing, from $4.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $9.0 million in Q4 2025 and troughed at $2.8 million in Q2 2022.
- A 5-year average of $5.4 million and a median of $5.4 million in 2021 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities plunged 56.36% in 2022, then soared 162.59% in 2023.
- Over 5 years, Total Liabilities stood at $3.3 million in 2021, then decreased by 16.45% to $2.8 million in 2022, then jumped by 162.59% to $7.3 million in 2023, then climbed by 13.89% to $8.3 million in 2024, then climbed by 8.71% to $9.0 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $9.0 million, $4.5 million, and $8.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 9.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.01 Mn |
| Jun 30, 2025 | 4.52 Mn |
| Dec 31, 2024 | 8.29 Mn |
| Jun 30, 2024 | 6.62 Mn |
| Dec 31, 2023 | 7.28 Mn |
| Jun 30, 2023 | 3.33 Mn |
| Dec 31, 2022 | 2.77 Mn |
| Jun 30, 2022 | 2.76 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Jun 30, 2021 | 6.32 Mn |
| Dec 31, 2020 | 4.09 Mn |
| Jun 30, 2020 | 9.25 Mn |
| Dec 31, 2019 | 14.58 Mn |
| Jun 30, 2019 | 4.87 Mn |
| Dec 31, 2018 | 4.53 Mn |
| Jun 30, 2018 | 17.00 Mn |
| Dec 31, 2017 | 19.31 Mn |
| Jun 30, 2017 | 10.82 Mn |
| Dec 31, 2016 | 13.63 Mn |
| Jun 30, 2016 | 22.80 Mn |